|
|
 |
|
Viewing report
|
|
|
|
Antithrombotics in Acute Ischemic Stroke - The Clot Thickens
Datamonitor, April 2003, Pages: 63
Introduction
Despite an incidence of over 1.7m in the seven major markets, the thrombolytic Activase (alteplase) is the only drug approved for ischemic stroke outside of Japan and has a three-hour therapeutic window, which means that only a minority of patients are eligible for therapy. Therefore, ischemic stroke is a potentially lucrative target market for pharmaceutical companies.
Scope
Estimates of the current and future incidence of acute ischemic stroke in the seven major markets
Discussion of current status of therapy and identification of the unmet needs with greatest commercial potential
Profiles of antithrombotics being trialed in acute ischemic stroke, analyzing their strengths and weaknesses in this indication
Comparative assessment of antithrombotics in development for stoke, in relation to alteplase, in terms of satisfaction of unmet need and potential
Report Highlights
With an estimated incidence of over 1.7m ischemic strokes in 2002 in the seven major markets and high unmet need, with just one drug approved outside of Japan for ischemic stroke, there is significant impetus for companies to trial agents in this indication.
In terms of developing safe and effective therapies for ischemic stroke, the greatest obstacle lies in extending the therapeutic window from the currently limited three hours to at least 6-12 hours.
In the absence of regenerative therapy, companies need to look beyond conventional single drug approaches and investigate which combinations of drugs and/or devices can achieve the best possible results in acute ischemic stroke.
Reasons to Purchase
Identify strategies for increasing the patient potential of antithrombotics in development for stroke
Identify the unmet needs that exist in the treatment of acute ischemic stroke and the extent that are likely to be met over the coming years
Understand which antithrombotics currently in development for acute ischemic stroke are the most promising and why
Customers who bought this item also bought
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Stakeholder Insight: Acute Stroke - TPA Spurs Infrastructure Changes for the Better
Target Product Profiles 2008: Physician Insights on Key Attributes - Acute Ischemic Stroke
Acute Stroke - Considerable Unmet Need is Balanced by Substantial Commercial Risk
Drugs, Devices and Procedures of Tomorrow: Acute Stroke - Chasing the need for speed
TPA in Stroke: Treatment Patterns and Potential
Treatment Algorithms 2001: Stroke - Time is Brain
Acute Stroke - Symptom Awareness Will Reduce Headache
Neuroprotection in Stroke - Protecting the Brain Sells
Strategic Perspectives: Marketed Antithrombotics - Plavix Adopts Lovenox's Developmental Defense Strategy
Stroke: Treatments and Prescribing Practices - A Global Survey 2009
Pipeline Insight: Antithrombotics - Reaching The Untreated Prophylaxis Market
|
|
|
|
